Cell activator
A cell activator is created from a purified fraction of deciduous dental pulp stem cell supernatant, focusing on components below 3.5 kDa and optimally 50 to 100 kDa, to enhance cell activation effects, overcoming the ambiguity of existing supernatants and improving cell proliferation and viability.
Patent Information
- Application Number
- JP2023086930
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-26
- Publication Date
- 2024-12-06
AI Technical Summary
The culture supernatant of deciduous dental pulp stem cells contains both active and inhibitory components, making it unclear which components are responsible for cell activation effects, and existing methods do not effectively separate these components.
A cell activator is developed comprising a fraction isolated from the culture supernatant of deciduous dental pulp stem cells, specifically containing components of less than 3.5 kDa, and preferably 50 to 100 kDa, while excluding components of 30 to 50 kDa and above 100 kDa, to enhance cell activation effects.
The purified cell activator is effective, safe, and inexpensive, exhibiting superior cell activation properties without inhibitory components, as demonstrated by increased intracellular dehydrogenase activity and cell proliferation in various cell types.
Smart Images

Figure 2024170020000001 
Figure 2024170020000002 
Figure 2024170020000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a cell activating agent. [Background technology]
[0002] It is known that the culture supernatant of mesenchymal stem cells (MSCs) contains various growth factors and cytokines, and it is expected that it will be useful in a wide range of fields, from cosmetics to regenerative medicine. MSCs can be easily extracted from various tissues such as bone marrow, dental pulp, adipose tissue, and umbilical cord, but in particular, deciduous dental pulp stem cells, which are MSCs extracted from deciduous teeth, can be easily prepared from deciduous teeth that have traditionally been discarded, and have high proliferation capacity, making them particularly promising as MSCs.
[0003] It has been reported that the culture supernatant of deciduous dental pulp stem cells is useful for repairing damaged tissues such as those caused by cerebral infarction and for protecting skin tissues (Patent Documents 1 and 2). However, it is not clear which components in the culture supernatant are the active components. In addition, the culture supernatant may contain components that act inhibitoryly against the active components, but these have not been clarified. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] International Publication No. 2011 / 118795 [Patent Document 2] International Publication No. 2014 / 126176 Summary of the Invention [Problem to be solved by the invention]
[0005] The present invention has been made with the objective of purifying the culture supernatant of deciduous dental pulp stem cells and providing a composition with excellent cell activation effects. [Means for solving the problem]
[0006] As a result of intensive research, the inventors have identified a fraction from the culture supernatant of deciduous dental pulp stem cells that has high cell activation activity and a fraction that inhibits cell activation activity, thereby completing the present invention.
[0007] That is, according to one embodiment, the present invention provides a cell activation agent comprising a fraction isolated from a culture supernatant of deciduous dental pulp stem cells, wherein the fraction does not contain components less than 3.5 kDa.
[0008] According to one embodiment, the present invention also provides the use of a fraction isolated from a culture supernatant of deciduous dental pulp stem cells as a cell activating agent, wherein the fraction does not contain components less than 3.5 kDa.
[0009] The fraction preferably contains a component of 50 to 100 kDa and does not contain a component of less than 30 kDa.
[0010] The fraction preferably does not contain components over 100 kDa and / or components between 30 and 50 kDa.
[0011] The deciduous dental pulp stem cells may be primary cultured cells.
[0012] Alternatively, the deciduous dental pulp stem cells may be immortalized cells.
[0013] Furthermore, according to one embodiment, the present invention provides a method for activating cells in a subject, the method comprising the step of administering to the subject the above-mentioned cell activation agent. Effect of the Invention
[0014] The cell activation agent of the present invention can be easily and inexpensively prepared from culture supernatant of deciduous dental pulp stem cells, and does not contain any components that inhibit cell activation activity, making it highly effective and safe, and useful. [Brief description of the drawings]
[0015] [Figure 1] FIG. 1 shows polyacrylamide gel electrophoretic images of SHED-CM and its fractions. [Diagram 2] FIG. 2 shows polyacrylamide gel electrophoretic images of IM-SHED-CM and its fractions. [Diagram 3] FIG. 3 is a graph showing the results of a WST assay evaluating the intracellular dehydrogenase activity of NIH3T3 cells cultured with SHED-CM fractions at different concentrations. [Figure 4] FIG. 4 is a graph showing the results of a WST assay evaluating the intracellular dehydrogenase activity of NIH3T3 cells cultured with IM-SHED-CM fractions at different concentration rates. [Diagram 5] FIG. 5 is a graph showing the results of a WST assay evaluating the intracellular dehydrogenase activity of NIH3T3 cells cultured with dilutions of SHED-CM or fractions thereof adjusted based on protein concentration. [Figure 6] FIG. 6 is a graph showing the results of a WST assay evaluating the intracellular dehydrogenase activity of NIH3T3 cells cultured with diluted solutions of IM-SHED-CM or fractions thereof adjusted based on the protein concentration. [Figure 7] FIG. 7 is a graph showing the results of a WST assay evaluating the intracellular dehydrogenase activity of NIH3T3 cells cultured with a dilution of the 50-100 kDa fraction derived from SHED-CM, the >100 kDa fraction, or the 30-50 kDa fraction. [Figure 8] FIG. 8 is a graph showing the results of a WST assay evaluating the intracellular dehydrogenase activity of NIH3T3 cells cultured with a dilution of the 50-100 kDa fraction derived from IM-SHED-CM, the >100 kDa fraction, or the 30-50 kDa fraction. [Figure 9] FIG. 9 shows the results of Western blot analysis comparing the expression levels and phosphorylation of MAPK in NIH3T3 cells cultured with SHED-CM / IM-SHED-CM or fractions thereof. [Figure 10]FIG. 10 shows the results of Western blot analysis comparing the expression levels and phosphorylation of Akt in NIH3T3 cells cultured with SHED-CM / IM-SHED-CM or fractions thereof. [Figure 11] FIG. 11 shows the results of Western blot analysis comparing the expression levels and phosphorylation of MAPK in NIH3T3 cells cultured with SHED-CM / IM-SHED-CM or fractions thereof at the same protein concentrations. [Figure 12] FIG. 12 shows the results of Western blot analysis comparing the expression levels and phosphorylation of Akt in NIH3T3 cells cultured with SHED-CM / IM-SHED-CM or fractions thereof at the same protein concentrations. [Figure 13] FIG. 13 shows the results of a scratch assay for NIH3T3 cells cultured with the addition of IM-SHED-CM or a fraction thereof. [Figure 14] FIG. 14 is a graph showing the results of a WST assay evaluating the intracellular dehydrogenase activity of NIH3T3 cells cultured with IM-SHED-CM or its >3.5 kDa fraction. [Figure 15] FIG. 15 shows the results of a scratch assay for NIH3T3 cells cultured with IM-SHED-CM or its >3.5 kDa fraction. [Figure 16] FIG. 16 is a graph showing the results of a WST assay evaluating the intracellular dehydrogenase activity of HUVECs cultured with diluted SHED-CM or its 50-100 kDa fraction adjusted based on protein concentration. [Figure 17] FIG. 17 is a graph showing the results of a WST assay evaluating the intracellular dehydrogenase activity of HUVECs cultured with diluted solutions of IM-SHED-CM or its 50-100 kDa fraction adjusted based on protein concentration. [Figure 18]FIG. 18 is a graph showing the intracellular dehydrogenase activity of HUVECs cultured with the 50-100 kDa fraction of SHED-CM or a mixture of the >100 kDa, 50-100 kDa and 30-50 kDa fractions. [Figure 19] FIG. 19 is a graph showing the intracellular dehydrogenase activity of HUVECs cultured with the 50-100 kDa fraction of SHED-CM, or a mixture of the 50-100 kDa and <30 kDa fractions. [Figure 20] FIG. 20 is a graph showing the intracellular dehydrogenase activity of HUVECs cultured with the 50-100 kDa fraction of IM-SHED-CM, or a mixture of the >100 kDa, 50-100 kDa, and 30-50 kDa fractions. [Figure 21] FIG. 21 is a graph showing the intracellular dehydrogenase activity of HUVECs cultured with the 50-100 kDa fraction of IM-SHED-CM, or a mixture of the 50-100 kDa and <30 kDa fractions. [Figure 22] FIG. 22 is a graph showing the results of a WST assay evaluating the inhibitory effect of IM-SHED-CM on cell damage caused by hydrogen peroxide treatment. [Diagram 23] FIG. 23 is a graph showing the results of a WST assay evaluating the inhibitory effect of the 50-100 kDa fraction of IM-SHED-CM on cell damage caused by hydrogen peroxide treatment. [Figure 24] FIG. 24 is a graph showing the results of a WST assay evaluating the inhibitory effect of the >100 kDa fraction of IM-SHED-CM on cell damage caused by hydrogen peroxide treatment. [Diagram 25] FIG. 25 is a graph showing the results of a WST assay evaluating the inhibitory effect of the 30-50 kDa fraction of IM-SHED-CM on cell damage caused by hydrogen peroxide treatment. [Figure 26] FIG. 26 is a graph showing the results of a quantitative analysis of the recovery of the scratches in FIGS. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] The present invention will be described in detail below, but the present invention is not limited to the embodiments described in the present specification.
[0017] According to a first embodiment, the present invention is a cell activation agent comprising a fraction isolated from a culture supernatant of deciduous dental pulp stem cells, wherein the fraction does not contain components less than 3.5 kDa.
[0018] In this embodiment, "cell activation" (and grammatical variants thereof) means normalizing or improving functions such as cell proliferation and metabolism. Therefore, "cell activation" in this embodiment may include, for example, activation of enzymes related to cell proliferation and metabolism (various dehydrogenases, Akt, AMPK, etc.) and enzymes that suppress oxidative stress (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and the like). Here, the "cell" may be in any vertebrate, preferably a mammalian cell such as a mouse, rat, rabbit, pig, cow, monkey, or human, and particularly preferably a human cell. The type of cell is not particularly limited, and may be, for example, a fibroblast, endothelial cell, epithelial cell, nerve cell, stem cell, leukocyte, bone cell, muscle cell, adipocyte, etc., and preferably a fibroblast or endothelial cell.
[0019] "Deciduous tooth dental pulp stem cells" are mesenchymal stem cells collected from the dental pulp of a deciduous tooth. The deciduous tooth dental pulp stem cells in this embodiment may be derived from any vertebrate, preferably from a mammal such as mouse, rat, rabbit, pig, cow, monkey, or human, and more preferably from human.
[0020] Methods for preparing deciduous dental pulp stem cells have already been established (eg, International Publication No. 2011 / 118795), and stem cells can be isolated and prepared from deciduous dental pulp according to methods known in the art.
[0021] In this embodiment, the deciduous dental pulp stem cells may be primary cultured cells or immortalized cells. "Immortalized cells" means that the cells maintain a proliferative state even after a certain number of divisions, that is, the cells have the ability to proliferate indefinitely. Methods for immortalizing cells have already been established, and known techniques can be used. For example, cells can be immortalized by introducing the SV40 T antigen gene or the telomerase reverse transcriptase (TERT) gene into the cells.
[0022] Methods for culturing deciduous dental pulp stem cells have already been established (for example, International Publication No. 2011 / 118795), and deciduous dental pulp stem cells can be cultured according to methods known in the art. Specifically, for example, 5×10 deciduous dental pulp stem cells can be cultured in a medium containing, as a basal medium, DMEM, IMDM, Ham's F-12, RPMI-1640, or a mixture thereof, appropriately supplemented with serum such as FBS or serum substitutes such as KSR, glucose, amino acids, vitamins, etc. 4 ~2×10 5 The deciduous dental pulp stem cells may be cultured by seeding them at a concentration of 1000 cells / mL. The cell activating agent of the present embodiment is preferably prepared from a culture supernatant obtained by culturing deciduous dental pulp stem cells in a serum-free medium.
[0023] The cell activator of this embodiment does not contain components of less than 3.5 kDa derived from the culture supernatant of deciduous dental pulp stem cells. Here, "not containing" means that the components to be removed are not detected by a commonly used detection means (e.g., immunochemical method, etc.). Therefore, the cell activator of this embodiment may be one in which at least 85% by weight, 90% by weight or more, 95% by weight or more, 97% by weight or more, 98% by weight or more, or 99% by weight or more of the components of less than 3.5 kDa contained in the unpurified culture supernatant have been removed. In other words, the cell activator of this embodiment may contain up to 15% by weight, less than 10% by weight, less than 5% by weight, less than 3% by weight, less than 2% by weight, or less than 1% by weight of the components of less than 3.5 kDa contained in the unpurified culture supernatant. The cell activator of this embodiment shows an improved cell activation effect by removing the components of less than 3.5 kDa from the culture supernatant of deciduous dental pulp stem cells.
[0024] In this embodiment, "kDa" may be calculated, for example, based on SDS-PAGE or ultrafiltration, and when the culture supernatant is purified using a commercially available ultrafiltration filter unit, it may be the nominal molecular weight cutoff (NMWL) or molecular weight cut-off (MWCO) value indicated on the product.
[0025] The cell activator of this embodiment preferably contains a fraction containing a component of 50 to 100 kDa; on the other hand, it is preferable that it does not contain a fraction containing a component of less than 30 kDa. It is more preferable that the cell activator of this embodiment does not contain a fraction containing a component of more than 100 kDa and / or a fraction containing a component of 30 to 50 kDa. This is because the component of 50 to 100 kDa has a higher cell activating activity, while not only the component of less than 3.5 kDa but also the component of more than 100 kDa and the component of 30 to 50 kDa may have an adverse effect on the cell activating activity of the component of 50 to 100 kDa.
[0026] The cell activator of the present embodiment can be prepared by combining ultrafiltration membranes of, for example, 100,000 MWCO, 50,000 MWCO, 30,000 MWCO and 3,500 MWCO. For example, by removing components of more than 100 kDa from culture supernatant using an ultrafiltration membrane of 100,000 MWCO, and concentrating the obtained filtrate using an ultrafiltration membrane of 50,000 MWCO, a cell activator can be prepared that contains the components of 50-100 kDa from the culture supernatant of deciduous dental pulp stem cells, but does not contain the components of 30-50 kDa and the components of less than 30 kDa.
[0027] The cell activation agent of this embodiment may be composed only of a fraction purified from the culture supernatant of deciduous dental pulp stem cells, but generally may further contain pharma- ceutically acceptable carriers and additives as optional components.
[0028] The cell activator of the present embodiment may be prepared as a liquid or solid agent, and may be formulated into various dosage forms such as injections, jellies, sprays, tablets, granules, etc., but is preferably prepared as a liquid agent. When prepared as a liquid agent, sterile water, physiological saline, glucose aqueous solution, etc. may be used as a carrier, and if desired, a bactericide, an isotonicity agent, a stabilizer, etc. may be added. When prepared as a solid agent, additives such as starch, lactose, mannitol, inorganic salts, and if desired, a binder, a disintegrant, a lubricant, etc. may be added.
[0029] In the cell activation agent of this embodiment, the content (converted into protein weight) of 50 to 100 kDa components derived from the culture supernatant of deciduous dental pulp stem cells may be, for example, 60% by weight or more, 70% by weight or more, 80% by weight or more, or 90% by weight or more, and preferably 60 to 70% by weight, when the total mass of the cell activation agent is 100%.
[0030] The cell activator of the present embodiment contains components derived from the culture supernatant of deciduous dental pulp stem cells that have cell activating activity, but does not contain components that inhibit the activity. Therefore, the cell activator of the present embodiment has a superior cell activating effect to the unpurified culture supernatant of deciduous dental pulp stem cells, and is useful.
[0031] According to a second embodiment, the present invention provides a method for activating cells in a subject, comprising administering to the subject the cell activation agent. In this embodiment, "activating cells" and "cells" are defined as in the first embodiment.
[0032] The "subject" in this embodiment may be any vertebrate, but is preferably a mammal such as a mouse, rat, rabbit, pig, cow, monkey, or human, and is particularly preferably a human. The subject may be of any age, including infants, juveniles, adolescents, adults, and geriatric subjects.
[0033] The cell activating agent in the method of this embodiment may be formulated into various dosage forms as defined in the first embodiment, and may be administered by any administration method suitable for the dosage form, for example, oral administration, intravenous administration, subcutaneous administration, transdermal administration, intramuscular administration, nasal administration, intraperitoneal administration, direct injection into target tissue, inhalation administration, etc. The dosage of the cell activating agent may vary depending on the age, weight, health condition, etc. of the subject, and may be, for example, 0.1 to 10 mg / kg (body weight), preferably 0.5 to 2 mg / kg (body weight). The dosage may be administered once or multiple times.
[0034] According to a third embodiment of the present invention, a fraction isolated from a culture supernatant of deciduous dental pulp stem cells is used as a cell activating agent, the fraction containing a component of 50-100 kDa and not containing a component of less than 30 kDa. In this embodiment, "deciduous dental pulp stem cells", "cell activating agent", "cell", "not containing" and "kDa" are the same as those defined in the first embodiment. According to the contents described in the first and second embodiments, a fraction derived from a culture supernatant of deciduous dental pulp stem cells containing a component of 50-100 kDa and not containing a component of less than 30 kDa can be used as a cell activating agent. EXAMPLES
[0035] The present invention will be further described below with reference to examples, but the present invention is not limited thereto.
[0036] <Materials and Reagents> NIH3T3 cells were purchased from the JCRB Cell Bank. Human umbilical vein endothelial cells (HUVEC), EBM TM -2 basal medium (CC-3156) and EGM TMA -2 supplement kit (CC-4176) was purchased from Lonza. Dulbecco's Modified Eagle Medium (DMEM) was purchased from GIBCO. Bovine Calf Serum (CS) and antimycotic solution (100x) were purchased from Sigma-Aldrich. Fetal bovine serum (FBS) and 0.05% trypsin / EDTA solution were purchased from Invitrogen. Charcoal (powder, activated) was purchased from Nacalai Tesque. Dulbecco's phosphate buffer (PBS), RIPA buffer, and quick CBB staining solution were purchased from Fujifilm Wako Pure Chemical. Ultrafiltration units (Vivaspin Turbo 15 membrane 30,000, 50,000, 100,000 MWCO) were purchased from SARTORIUS. Millex-GV low protein binding durapore (PVDF) Membrane 0.22 μm was purchased from Merck Millipore. TM 7 Dialysis Membrane (MWCO: 3.5kD) was purchased from REPLIGEN. PD-10 columns were purchased from Cytiva. Micro BCA Protein Assay Kit was purchased from Thermo Fisher Scientific. Cell Counting Kit-8 was purchased from Dojindo Laboratories. Acrylamide, protein standard markers and Clarity Western ECL Substrate were purchased from Bio-Rad. Protease inhibitor complete (#11 697 498 001) was purchased from Roche. Anti-phospho p44 / 42 antibody (#9106) and anti-phospho Akt antibody (#9271) were purchased from Cell Signaling Technology. Anti-mouse IgG-HRP antibody (#62-6520) and anti-rabbit IgG-HRP antibody (#65-6120) were purchased from Invitrogen.
[0037] <1. Preparation of culture supernatant of stem cells derived from deciduous dental pulp and its fraction> (1-1) Preparation of stem cells derived from human deciduous dental pulp (SHED) Lost or extracted human deciduous teeth were disinfected with 5% chlorhexidine solution (Yamazen Pharmaceuticals) or 10% povidone-iodine solution (Iwaki Pharmaceuticals), the crowns were divided, and the dental pulp tissue was collected using a dental reamer. The dental pulp tissue was suspended in DMEM containing 10% FBS by volume, and 2 mg / ml collagenase (Fujifilm Wako Pure Chemical Industries, Ltd.) and dispase (Fujifilm Wako Pure Chemical Industries, Ltd.) were added, and the tissue was incubated at 37°C for 1 hour. The tissue was centrifuged at 777 x g for 5 minutes, the supernatant was removed, and dental pulp cells were collected. The tissue was then washed with 10% FBS by volume and 1% antibiotic-antimycotic agent (Gibco TM Dental pulp cells were suspended in DMEM (4 mL) supplemented with antibiotic-antimycotic and seeded in a 6-well plate. The cells were cultured at 37°C under 5% CO2 conditions until they became subconfluent. 0.05% trypsin / EDTA solution was added and incubated at 37°C for 5 minutes, after which the cells were harvested and seeded in a 10 cm dish for adherent cells (Violamo). They were then subcultured three times, yielding approximately 1 × 10 7 The cells were grown until they became cells. A 0.05% trypsin / EDTA solution was added and incubated at 37°C for 5 minutes. The collected cells were named "SHED (Stem cells from Human Exfoliated Deciduous teeth)".
[0038] (1-2) Preparation of immortalized human deciduous dental pulp-derived stem cells (IM-SHED) SHED immortalized by introducing the SV40 gene via a viral vector (IM-SHED) was prepared by Applied Biological Materials.
[0039] (1-3) Preparation of culture supernatant The SHED or IM-SHED prepared above was subcultured in DMEM containing 10% FBS by volume. For the preparation of culture supernatant, SHED that had been subcultured up to 8 times and IM-SHED that had been subcultured 50 to 55 times were used. The medium was replaced with serum-free DMEM and cultured for 48 hours. Thereafter, the medium was collected and filtered through a separation membrane (Stericup Quick Release-GP, PVDF, 0.22 μm; Merck Millipore) to obtain a culture supernatant (conditioned medium: CM). Hereafter, the culture supernatant derived from SHED is referred to as "SHED-CM" and the culture supernatant derived from IM-SHED is referred to as "IM-SHED-CM".
[0040] (1-4) Fractionation and concentration of culture supernatant The CM was centrifuged at room temperature at 1,000 rpm for 3 min; at 500 × g at 4 °C for 30 min; and at 2,000 × g at 4 °C for 30 min, and then filtered through Millex-GV low protein binding durapore (PVDF) Membrane 0.22 μm to remove impurities such as cells. The CM was then subjected to a 100,000 MWCO ultrafiltration unit and centrifuged at 2,000 × g at 4 °C for 20 min. The filtrate (hereinafter referred to as "PT") was subjected to a 50,000 MWCO ultrafiltration unit and centrifuged at 2,000 × g at 4 °C for 20 min. The PT was subjected to a 30,000 MWCO ultrafiltration unit and centrifuged at 2,000 × g at 4 °C for 20 min.
[0041] Further, 10 mL of PBS was added to the 100,000 MWCO ultrafiltration unit and centrifuged at 4°C, 2,000×g for 20 minutes. This was repeated five times to obtain a >100 kDa fraction concentrate. The PT obtained here was fed to the 50,000 MWCO ultrafiltration unit and centrifuged at 4°C, 2,000×g for 20 minutes to obtain a 50-100 kDa fraction concentrate. The PT was fed to the 30,000 MWCO ultrafiltration unit and centrifuged at 4°C, 2,000×g for 20 minutes to obtain a 30-50 kDa fraction concentrate. The PT was fed to a PD-10 column, the buffer was replaced with PBS, and a <30 kDa fraction was obtained. The fraction concentrate was freeze-dried, dissolved in Milli-Q water, sample buffer (with or without SDS) was added, and electrophoresis was performed on a 12.5% polyacrylamide gel.
[0042] The results of electrophoresis of SHED-CM and its fractions are shown in Figure 1, and the results of electrophoresis of IM-SHED-CM and its fractions are shown in Figure 2. It was confirmed that both SHED-CM and IM-SHED-CM contain many protein components in the 50-100 kDa fraction.
[0043] 2. Activation of cell proliferation and viability by SHED-CM / IM-SHED-CM fractions (WST assay) Activated carbon-treated CS (hereinafter referred to as "CH-CS") was prepared by the following procedure: 10 mg of activated carbon was added to 1 mL of CS and gently vortexed for 15 seconds. After incubation at 37 °C for 10 minutes, the mixture was centrifuged at 4 °C and 12,000 rpm for 20 minutes, and the supernatant was subjected to a 0.22 μm PVDF filter to obtain CH-CS. NIH3T3 cells were seeded (5,000 cells / well) in a 96-well plate (Violamo) and cultured overnight in 10% CS / DMEM. To serum-starve the cells, the medium was replaced with 0.4% CH-CS / DMEM, and the cells were cultured for 24 hours. The fraction prepared in 1 above was then diluted with 0.4% CH-CS / DMEM and added, and the cells were cultured for 44 hours. WST solution (10 μL / well) of Cell Counting Kit-8 was added, and the cells were further cultured for 4 hours, after which the absorbance at 450 nm was measured.
[0044] The results are shown in Figures 3 and 4. An increase in absorbance at 450 nm indicates an increase in the activity of intracellular dehydrogenases, and the higher the absorbance at 450 nm, the higher the cell proliferation and viability. In the figures, "10%CS" means 10%CS / DMEM, and "CM x 1 / 2 dil." means a medium in which CM was diluted 1 / 2 with 0.4% CH-CS / DMEM. These results indicate that the 50-100 kDa fraction of both SHED-CM and IM-SHED-CM contains components that activate cell proliferation and viability. Similar results were obtained with HeLa cells, a cell line derived from human cervical cancer, human bone marrow-derived mesenchymal stem cells, and human iPS cells (409B2 line) (data omitted).
[0045] Furthermore, the results of comparing the activity of each fraction at the same protein concentration are shown in Figures 5 and 6. In the figures, "Calculated value" indicates the value obtained by correcting the CM result by the protein concentration of each fraction calculated from the electrophoresis result in 1 above and the protein concentration quantification result using the Micro BCA Protein Assay Kit. It was revealed that among the fractions purified from SHED-CM and IM-SHED-CM, only the 50-100 kDa fraction contains components that activate cell proliferation and viability.
[0046] 3. Inhibition of cell proliferation and viability by SHED-CM / IM-SHED-CM fractions The 50-100 kDa fraction prepared in 1 above was diluted with 0.4% CH-CS / DMEM, the >100 kDa fraction, or the 30-50 kDa fraction, and the intracellular dehydrogenase activity was evaluated by the same procedure as in 2 above.
[0047] The results are shown in Figures 7 and 8. The activity of dehydrogenase in cells was reduced by mixing the 50-100 kDa fraction with the >100 kDa fraction or the 30-50 kDa fraction. In particular, the inhibitory effect of the 30-50 kDa fraction derived from IM-SHED was large (Figure 8), suggesting the presence of a factor that inhibits the proliferation and viability of cells.
[0048] 4. Activation of intracellular signal transduction by SHED-CM / IM-SHED-CM fractions NIH3T3 cells were seeded in 12-well plates (6 × 10 4Cells were cultured overnight in 10% CS / DMEM (cells / well). To serum starve the cells, the medium was replaced with 0.4% CH-CS / DMEM and cultured for 24 hours. The CM or its fraction prepared in 1 above was then diluted with 0.4% CH-CS / DMEM and added. For controls, 10% FBS or human TNFα (PeproTech) (50 ng / mL) was added. After 30 minutes of culture, the cells were washed twice with PBS and lysed with RIPA buffer supplemented with protease inhibitors. The cell lysate was collected in a microtube and shaken for 30 minutes at 4°C. The cells were centrifuged at 15,000 rpm at 4°C for 20 minutes, and the supernatant was collected. SDS-containing sample buffer was added, and the cells were incubated at 95°C for 5 minutes, followed by electrophoresis on a 10% polyacrylamide gel. After transferring the proteins to a nitrocellulose membrane, it was blocked with 5% skim milk / TBST solution (room temperature, 1 hour). The nitrocellulose membrane was then incubated overnight at 4°C in the primary antibody solution. The primary antibody solution was removed, and the nitrocellulose membrane was washed three times with TBST, after which it was incubated at room temperature for 1 hour in the secondary antibody solution. Anti-phospho p44 / 42 antibody (1:2000) or anti-phospho Akt antibody (1:2000) was used as the primary antibody, and anti-mouse IgG-HRP antibody (1:5000) or anti-rabbit IgG-HRP antibody (1:5000) was used as the secondary antibody. Clarity Western ECL Substrate was used for detection reaction.
[0049] The results are shown in Figures 9 and 10. The addition of the 50-100 kDa fraction significantly increased the expression and phosphorylation of MAPK and Akt. Figures 11 and 12 show the results of comparing CM and the 50-100 kDa fraction prepared at the same protein concentration. Compared to CM, the 50-100 kDa fraction increased phosphorylation. These results indicate that the 50-100 kDa fraction activates phosphorylation signaling in cells.
[0050] 5. Activation of cell migration by SHED-CM / IM-SHED-CM fractions (scratch assay) NIH3T3 cells were seeded in 48-well plates (3.75 × 10 4 Cells were cultured overnight in 10% CS / DMEM (cells / well). To serum starve, the medium was replaced with 0.4% CH-CS / DMEM and cultured for 24 h. Scratches were made in a straight line on the cell monolayer using a 200 μL pipette tip. After washing twice with DMEM, CM (diluted 1 / 2 with 0.4% CH-CS / DMEM); 10% FBS / DMEM; or fractions of >100 kDa, 50-100 kDa, or 30-50 kDa (diluted with 0.4% CH-CS / DMEM to a protein concentration 5-fold higher than the original solution) were added and cultured for 24 h.
[0051] The results (microscope images) are shown in Figure 13. Furthermore, the cell areas in the microscope images were digitized using ImageJ software, and the results of quantitative analysis are shown in Figure 26. It was confirmed that the 50-100 kDa fraction retained wound healing activity equivalent to that of CM.
[0052] 6. Preparation and analysis of ≥3.5 kDa fraction of IM-SHED-CM IM-SHED-CM to Spectra / Por TM The resulting solution was lyophilized, dissolved in 1 / 10 the starting volume of PBS (on ice for >30 min), and filtered through a 0.22 μm PVDF filter. The activity of the resulting ≥3.5 kDa fraction against intracellular dehydrogenases and cell migration was evaluated using the same procedures as in 2 and 5 above.
[0053] The results of the WST assay are shown in Figure 14. The ≥3.5 kDa fraction prepared at a high protein concentration (100 μg / mL) activated intracellular dehydrogenases more than CM prepared at the same protein concentration. The results of the scratch assay are shown in Figure 15, and the results of the quantitative analysis are shown in Figure 26. The ≥3.5 kDa fraction significantly increased cell migration to the scratch. These results indicate that by removing the <3.5 kDa fraction, it is possible to obtain a cell activation effect equal to or greater than that of CM.
[0054] 7. Activation of cell proliferation and viability by SHED-CM / IM-SHED-CM fractions (2) Using HUVECs instead of NIH3T3 cells, the activation of intracellular dehydrogenases by the 50-100 kDa fraction purified from SHED-CM and IM-SHED-CM was evaluated by the same procedure as above 2. HUVECs were cultured in the same manner as in EBM TM -2 basal medium (CC-3156) and EGM TM The cells were grown in a 10 cm dish for adherent cells to 80-90% confluence using the medium prepared by the -2 supplement kit (hereinafter referred to as "EGM-2 medium"), detached with 0.05 trypsin / EDTA solution, and collected. The cells were suspended by adding EGM-2 medium, and the cell number and cell viability were measured using the Countess2 automatic cell counter and trypan blue, and the concentration of the cell suspension was adjusted to 25,000 cells / mL. The cells were seeded in a 96-well plate (100 μL / well). After one day, the medium was replaced with EGM-2 medium supplemented with CM or 50-100 kDa fraction. After culturing for 3 days, WST solution (10 μL / well) from Cell Counting Kit-8 was added, and the absorbance at 450 nm was measured after 3-4 hours of culturing.
[0055] The results are shown in Figures 16 and 17. In the figures, "Calculated value" indicates the value obtained by correcting the results of CM by the protein concentration of each fraction calculated from the electrophoresis results in 1 above and the quantification results of protein concentration using the Micro BCA Protein Assay Kit. Both the 50-100 kDa fractions derived from SHED-CM and IM-SHED-CM increased intracellular dehydrogenase activity more than CM at the same protein concentration. This result indicated that the 50-100 kDa fractions derived from SHED-CM and IM-SHED-CM contain components that activate the proliferation and viability of HUVEC.
[0056] <8. Inhibition of cell proliferation and viability by SHED-CM / IM-SHED-CM fractions (2)> A mixture of the >100 kDa, 50-100 kDa, and 30-50 kDa fractions (mixing ratio 1:1:1), and a mixture of the 50-100 kDa and <30 kDa fractions (mixing ratio 1:1) were prepared. The 50-100 kDa fraction and the above mixture were serially diluted with EGM-2 medium, and the intracellular dehydrogenase activity was evaluated by the same procedure as in 7 above.
[0057] The results of the SHED-CM-derived fraction and its mixture are shown in Figures 18 and 20, and the results of the IM-SHED-CM-derived fraction and its mixture are shown in Figures 19 and 21. In the figures, "Mix >100,50,30kDa" means a mixture of >100kDa, 50-100kDa and 30-50kDa fractions, "Mix 50kDa,30PT" means a mixture of 50-100kDa and <30kDa fractions, and "50kDa" means the 50-100kDa fraction. In the mixed solution of >100kDa, 50-100kDa and 30-50kDa fractions, no significant decrease in intracellular dehydrogenase activity was observed compared to the 50-100kDa fraction (Figures 18 and 20). In contrast, the mixed solution of the 50-100 kDa and <30 kDa fractions showed a significant decrease in intracellular dehydrogenase activity compared to the 50-100 kDa fraction (Figures 19 and 21). These results demonstrated that the <30 kDa components in CM inhibited the proliferation and viability of HUVECs.
[0058] 9. Inhibitory effect of IM-SHED-CM fraction on hydrogen peroxide-induced cell injury HUVECs were grown in 10 cm dishes for adherent cells in EGM-2 medium to 80-90% confluence, detached with 0.05 trypsin / EDTA solution, and harvested. EGM-2 medium was added to suspend the cells, and the cell number and cell viability were measured using a Countess2 automated cell counter and trypan blue, and the concentration of the cell suspension was adjusted to 50,000 cells / mL. The cells were seeded in a 96-well plate (100 μL / well). After 1 day, the medium was replaced with serial dilutions of IM-SHED-CM and their fractions in EGM-2 medium and cultured for 3 days. Hydrogen peroxide (final concentration 0.005-0.00031%) was added to the cells and incubated at 37 °C for 1 hour. The dilution solution was removed, and EGM-2 medium (100 μL / well) and Cell Counting Kit-8 WST solution (10 μL / well) were added. After 3 to 4 hours of culture, the absorbance at 450 nm was measured.
[0059] The results for cells to which serial dilutions of IM-SHED-CM were added are shown in Figure 22. In cells to which IM-SHED-CM was not added (control), the absorbance at 450 nm was reduced by hydrogen peroxide treatment, and the decrease was even greater in a hydrogen peroxide concentration-dependent manner. This result confirmed cell damage caused by hydrogen peroxide treatment. On the other hand, in cells to which serial dilutions of IM-SHED-CM were added, the absorbance at 450 nm was reduced in a hydrogen peroxide concentration-dependent manner, but the decrease in absorbance at 450 nm was suppressed compared to the control. This result confirmed that IM-SHED-CM suppressed cell damage caused by oxidative stress.
[0060] The results for cells to which serial dilutions of the 50-100 kDa fraction of IM-SHED-CM were added are shown in Figure 23, the results for cells to which serial dilutions of the >100 kDa fraction were added are shown in Figure 24, and the results for cells to which serial dilutions of the 30-50 kDa fraction were added are shown in Figure 25. In cells to which the 50-100 kDa fraction was added, the absorbance at 450 nm increased in a protein concentration-dependent manner, indicating that cell damage due to oxidative stress was suppressed in a concentration-dependent manner of the 50-100 kDa fraction.
Claims
1. A cell activating agent comprising a fraction isolated from a culture supernatant of deciduous dental pulp stem cells, said fraction not containing any component less than 3.5 kDa.
2. The cell activating agent according to claim 1, wherein the fraction contains a component of 50 to 100 kDa and does not contain a component of less than 30 kDa.
3. The cell activating agent according to claim 1 or 2, wherein the fraction does not contain components of more than 100 kDa and / or components of 30 to 50 kDa.
4. The cell activating agent according to any one of claims 1 to 3, wherein the deciduous dental pulp stem cells are primary cultured cells.
5. The cell activating agent according to any one of claims 1 to 3, wherein the deciduous dental pulp stem cells are immortalized cells.
6. A method for activating cells in a subject, the method comprising the step of administering to the subject a cell activating agent according to any one of claims 1 to 5.
7. 2. Use of a fraction isolated from a culture supernatant of deciduous dental pulp stem cells as a cell activating agent, wherein the fraction does not contain components less than 3.5 kDa.
8. The use according to claim 7, wherein the fraction comprises components of 50 to 100 kDa and does not comprise components of less than 30 kDa.
9. The use according to claim 7 or 8, wherein the fraction is free of components above 100 kDa and / or components between 30 and 50 kDa.
10. The use according to any one of claims 7 to 9, wherein the deciduous dental pulp stem cells are primary cultured cells.
11. The use according to any one of claims 7 to 9, wherein the deciduous dental pulp stem cells are immortalized cells.
Citation Information
Patent Citations
Composition for treatment of damaged part
WO2011118795A1
Composition for preventing or treating inflammatory disease
WO2014126176A1
Cited By
Bfgf production method
WO2025159096A1
